Immunocore Holdings Reports Q2 2026 Financial Results

What Happened
Immunocore Holdings plc announced its financial results for the quarter ended June 30, 2026 by issuing a press release dated August 6, 2026. The company filed an 8‑K (Item 2.02) to furnish that press release (Exhibit 99.1) and included the Inline XBRL cover page (Exhibit 104). The filing was signed by CEO Bahija Jallal, Ph.D.

Key Details

• Filing date: August 6, 2026; reporting results for the quarter ended June 30, 2026.
• Press release furnished as Exhibit 99.1 to the Form 8‑K.
• Inline XBRL cover page included as Exhibit 104.
• Form 8‑K executed by Chief Executive Officer Bahija Jallal, Ph.D.

Why It Matters
This 8‑K is the company’s formal disclosure of its quarterly operating and financial results to investors. Retail investors should review the furnished press release (Exhibit 99.1) for specific metrics—revenue, earnings/loss, cash position, guidance and any corporate updates—that may affect valuation and near‑term trading. The 8‑K itself does not add analysis or projections; it publicly documents that those results and updates have been released.